Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SLN Transcript
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
Silence Therapeutics plc (NASDAQ:SLN) Q4 2024 Earnings Call Transcript
Unknown3-3
The earnings call highlights financial challenges, such as a net operating loss and dependency on securing a partner for Phase 3 studies, which could delay progress. Despite increased revenue, the company's financial health remains precarious with significant R&D expenses. The Q&A section reveals management's reluctance to provide clarity on partnerships, raising concerns about execution risks. These factors, combined with competitive market pressures and supply chain challenges, suggest a negative sentiment towards the stock's short-term performance.
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Unknown2-28
The earnings call reveals moderate revenue growth and improved net loss, but lacks strong catalysts like new partnerships or guidance upgrades. Management's vague responses in the Q&A and uncertainties around partnerships and competition present potential risks. The decision to delay the Phase 3 trial until a partner is secured extends the cash runway, but doesn't provide immediate positive impact. Overall, the mixed signals and lack of decisive positive news suggest a neutral sentiment for the stock price over the next two weeks.
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Unknown3-13
The earnings call revealed mixed signals. The company reported strong revenue growth and secured significant milestone payments, indicating positive financial performance. However, rising R&D costs and net losses are concerning. The Q&A section highlighted operational challenges and competitive pressures but also showed promising clinical data and potential partnerships. Overall, the sentiment is neutral due to the balance of positive revenue growth and financial challenges, along with the cautious tone in the Q&A section.
SLN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
